Trials / Completed
CompletedNCT00168701
Efficacy and Safety of BG00012 in MS
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Determine the efficacy, safety, and tolerability of BG00012 in MS patients.
Detailed description
The study will be divided into two parts: Part 1 will be a 24-week, blinded, placebo-controlled treatment phase followed by Part 2, a 24-week blinded, safety extension phase in which all subjects will receive BG00012.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BG00012 |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2006-03-31
- Completion
- 2006-03-31
- First posted
- 2005-09-15
- Last updated
- 2023-08-28
Locations
42 sites across 10 countries: Czechia, Germany, Hungary, Netherlands, Poland, Russia, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00168701. Inclusion in this directory is not an endorsement.